4527
ROHTO PHARMACEUTICAL CO.,LTD.
ロート製薬
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Notes
- Stock adjustmentsJan 1, 2023 Stock split 1 share → 2 shares
Key metrics
Revenue(million JPY)
Mar 2022
199,646
Mar 2023
238,664
Mar 2024
270,840
Mar 2025
308,625
Mar 2026
343,725
Operating profit(million JPY)
Mar 2022
29,349
Mar 2023
33,959
Mar 2024
40,048
Mar 2025
38,939
Mar 2026
41,118
Operating profit margin(%)
Mar 2022
14.7
Mar 2023
14.23
Mar 2024
14.79
Mar 2025
12.62
Mar 2026
11.96
Profit before tax(million JPY)
Mar 2022
27,953
Mar 2023
34,290
Mar 2024
41,518
Mar 2025
42,331
Mar 2026
46,821
Profit(million JPY)
Mar 2022
21,018
Mar 2023
26,377
Mar 2024
30,936
Mar 2025
31,006
Mar 2026
34,247
Total assets(million JPY)
Mar 2022
274,627
Mar 2023
309,677
Mar 2024
346,175
Mar 2025
421,875
Mar 2026
485,771
Cash and cash equivalents(million JPY)
Mar 2022
70,905
Mar 2023
77,691
Mar 2024
86,562
Mar 2025
73,221
Mar 2026
82,851
Cash flows from operating activities(million JPY)
Mar 2022
27,250
Mar 2023
30,924
Mar 2024
34,245
Mar 2025
36,917
Mar 2026
47,788
Cash flows from investing activities(million JPY)
Mar 2022
-16,406
Mar 2023
-13,176
Mar 2024
-16,317
Mar 2025
-89,170
Mar 2026
-29,780
Cash flows from financing activities(million JPY)
Mar 2022
3,470
Mar 2023
-16,199
Mar 2024
-13,784
Mar 2025
35,319
Mar 2026
-11,845
Return on equity(%)
Mar 2022
12.6
Mar 2023
13.6
Mar 2024
13.6
Mar 2025
12.3
Mar 2026
12.1
Equity ratio(%)
Mar 2022
64.8
Mar 2023
67.6
Mar 2024
71
Mar 2025
61.6
Mar 2026
62.1
Earnings per share(JPY per share)
Mar 2022
92.13
Mar 2023
115.62
Mar 2024
135.61
Mar 2025
136.11
Mar 2026
151.56
Net assets per share(JPY per share)
Mar 2022
779.81
Mar 2023
916.93
Mar 2024
1,078.04
Mar 2025
1,149.35
Mar 2026
1,334.04
Dividend per share(JPY per share)
Mar 2022
18
Mar 2023
22
Mar 2024
27
Mar 2025
36
Mar 2026
46
Payout ratio(%)
Mar 2022
19.54
Mar 2023
19.03
Mar 2024
19.91
Mar 2025
26.45
Mar 2026
30.35
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.